Lauromacrogol 400 50mg / Heparinoid 4mg suppositories

Objectives: To explore the safety and efficacy of injections of 1%, 2%, or 3% lauromacrogol during EUS-guided lauromacrogol ablation (EUS-LA) for the treatment of pancreatic cystic neoplasms (PCNs) and to determine the optimal concentration of lauromacrogol for use in EUS-LA therapeutic regimens. Methods: From May 2021 to January 2023, patients who met the indications for EUS-LA were randomly divided into 3 groups: A, B, and C; the patients in these groups were injected with 1%, 2%, and 3% lauromacrogol during EUS-LA, respectively. Safety was evaluated based on the incidence of postoperative complications. Efficacy was comprehensively evaluated by assessing the ablation rate and ablation effect. Results: Forty-two patients underwent EUS-LA, and 31 patients completed at least 1 postoperative re-examination. No acute pancreatitis was observed in the 1% and 2% lauromacrogol groups, and 1 case of acute pancreatitis occurred in the 3% lauromacrogol group. The total complication rate was 2.4%. The median ablation rates of the groups were 94.1%, 82.0%, and 100.0%, respectively. There were statistically significant differences in the EUS-LA ablation rate between the 1% and 3% lauromacrogol groups and between the 2% and 3% lauromacrogol groups. There was a statistically significant difference in complete disappearance between the 1% and 3% lauromacrogol groups as well as between the 2% and 3% lauromacrogol groups. Conclusion: The short-term outcomes showed that injections of 1%, 2%, and 3% lauromacrogol were safe for use in EUS-LA, and injection of 3% lauromacrogol was the most effective for EUS-LA.

Abstract licence: CC BY-NC-ND

Annotation. Varicose veins of the lower extremities tend to be more common in older age groups, whose treatment is complicated by comorbidity and advanced pathology. The aim is to develop an effective, safe and economical method of treating varicose veins of the lower extremities in elderly and senile patients. We monitored 69 patients who underwent scleroobliteration and compression therapy. The first group – 31 patients aged 67-83 years with pronounced comorbidity, limited mobility and difficulties with the use of compression knitwear. The aescinic salt of 2,6-diaminohexanoic acid was used in the form of a 0.1% solution. After the session, an elastic bandage, a compression product of 15–20 mm Hg, or a combination thereof was applied to the lower leg. The patients followed the movement regime available to them. The second group – 38 patients aged 23-51 years. Lauromacrogol 400 (polidocanol) was used in the form of a foam form of a 3% solution. After the session, a compression product of 23-32 mm Hg was used. Statistical methods of processing: Student’s test and Fisher's angle transformer. It was found that course of the scleroobliteration session (character, duration and intensity of pain), early (sensation along the course of sclerosed veins, their nature, intensity and duration) and long-term (disappearance or degree of reduction of varicose veins, tissue condition in the area of sclerosed veins, frequency of recanalization) periods after scleroobliteration in patients of both groups was identical. In 16 patients of the 1st group, compression was performed for less time and not in full. Among them, thrombophlebitis occurred in one patient. Among the patients of the II group, compression defects were observed in 3 cases. Two of them developed thrombophlebitis (p<0.01). So staged scleroobliteration in the complex treatment of varicose veins of the lower extremities is an effective, safe, low-traumatic, simple, economical outpatient technology. Aescinic salt of 2,6-diaminohexanoic acid should be considered the drug of choice for scleroobliteration in elderly patients with limited mobility.

Abstract licence: CC BY

Relevance. Retention cysts of the salivary glands are a frequent occurrence in dental practice. Traditional treatments, such as cystadenectomy and cystotomy, are commonly employed. However, these procedures are associated with postoperative complications, including recurrence, damage to adjacent structures (e.g., ducts of neighbouring salivary glands, blood vessels, and nerves), and inadvertent opening of the submandibular salivary gland capsule. Description of clinical cases. This paper presents clinical cases of four pediatric patients diagnosed with retention cysts of the salivary glands, treated at the Department of Pediatric Maxillofacial Surgery, Russian University of Medicine. All patients received treatment with "Lauromacrogol-400" ("Ethoxysclerol") and "Bleomycin." In the postoperative period, no complications or adverse effects related to the administered drugs were observed. Follow-up examinations revealed no clinical manifestations of retention cysts or ultrasonographic evidence of cysts. Conclusions. Sclerotherapy using "Ethoxysclerol" and "Bleomycin" for the treatment of retention cysts of the salivary glands presents a viable minimally invasive alternative to conventional surgical methods, potentially mitigating the risks associated with more invasive procedures.

Abstract licence: CC BY

Introduction: In vivo screening studies, in which the efficacy of dozens of drugs is tested to select several applicants for further study of their safety in humans, are the main stage in the study of the pharmacodynamics of promising antiglaucoma drugs. This imposes a number of specific requirements both on experimental models of glaucoma and on laboratory animals used in the experiment.
 Materials and Methods: 32 male rabbits of the Soviet Сhinchilla breed, 6 male albino rabbits weighing 3-3.5 kg, and 20 outbred white rats weighing 220-250 g were used in total in experiments to reproduce the glaucoma process. All manipulations on the rabbit eye were performed by an ophthalmologist under general anesthesia with telazol. Triamcinolone (vitreous injection) was used to simulate glaucoma in rabbits, lauromacrogol 400 or fine kaolin (anterior chamber injection) was used to simulate glaucoma in rabbits; adrenaline hydrochloride (intraperitoneal administration) was used to simulate glaucoma in rats.
 Results and Discussion: Double intravitreal administration of a suspension of triamcinolone at a dose of 4 mg was the most attractive model in terms of the technique of reproducing the pathology and the results obtained in modeling glaucoma in rabbits. However, this model did not produce a stable increase in intraocular pressure (IOP). Doubling the dose of triamcinolone and replacing chinchilla rabbits with albinos did not lead to a positive result. The introduction of the venous sclerosing drug lauromacrogol 400 into the anterior chamber of the eye proved to be ineffective either. The introduction of finely dispersed kaolin into the anterior chamber of the eye of rabbits led to a persistent increase in IOP. The intraperitoneal administration of epinephrine hydrochloride to rats according to the described method gave no stable results. The increase in IOP became stable only after a significant increase in the dose of adrenaline.
 Conclusion: The conducted studies of four models of glaucoma and their three modifications in animals made it possible to select two of them, which contributed to a stable and fairly long-term increase in IOP in rabbits (introduction of finely dispersed kaolin into the anterior chamber of the eye) and rats (adrenaline-induced model).

Abstract licence: CC BY